Odeh Ayham, Verm Raymond, Park Simon, Swanson James, Baker Marshall, Abdelsattar Zaid
Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois; Department of General Surgery, Ascension St. Vincent; Indianapolis, Indiana.
Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois.
Ann Thorac Surg. 2025 Sep;120(3):521-529. doi: 10.1016/j.athoracsur.2024.11.004. Epub 2024 Nov 12.
Patients may receive their adjuvant therapy at a facility different from where they had their lung cancer operation. Whether this fragmentation of care affects outcomes is unclear.
We used the National Cancer Database to identify lung cancer patients undergoing resection and adjuvant chemotherapy from 2006-2020. We stratified patients into those receiving fragmented care or not, and further divided fragmented care patients by the Commission on Cancer (CoC) accreditation status of the hospital. Fragmented care refers to patients receiving surgery and chemotherapy at different institutions. These institutions can be either CoC accredited or not. The main outcome was overall survival. We used Kaplan-Meier analysis to estimate survival and multivariable and Cox proportional models to identify associations.
Of 65,369 patients, 32,494 (49.7%) had fragmented care, with the majority (70.4%) receiving their chemotherapy at a non-CoC accredited facility. Factors associated with fragmented care were White race (adjusted odds ratio [aOR], 1.34; P < .001), lower comorbidity index (aOR, 1.11; P < .001), having private insurance (aOR, 1.11; P < .001), and a higher median income (aOR, 1.24 P < .001). Fragmented care was associated with worse overall survival (median survival, 60 vs 65 months; P < .001) compared with single-center care. When care was fragmented, receiving adjuvant chemotherapy at CoC-accredited centers had higher 5-year overall survival rates compared with those with fragmented care at non-CoC centers (median survival, 71 vs 55 months; P < .001).
The majority of lung cancer patients have their care fragmented to non-CoC-accredited centers and this is associated with worse outcomes. Regionalization, achieving CoC accreditation, or improved patient access may be necessary to allow select patients to receive closer care while maintaining outcomes.
患者可能在与肺癌手术地点不同的机构接受辅助治疗。这种医疗服务的碎片化是否会影响治疗结果尚不清楚。
我们使用国家癌症数据库识别2006年至2020年期间接受手术切除和辅助化疗的肺癌患者。我们将患者分为接受碎片化治疗和未接受碎片化治疗的两组,并根据医院癌症委员会(CoC)的认证状态进一步划分接受碎片化治疗的患者。碎片化治疗是指患者在不同机构接受手术和化疗。这些机构可以是经过CoC认证的,也可以是未经认证的。主要结局是总生存期。我们使用Kaplan-Meier分析来估计生存率,并使用多变量和Cox比例模型来确定关联。
在65369例患者中,32494例(49.7%)接受了碎片化治疗,其中大多数(70.4%)在未经CoC认证的机构接受化疗。与碎片化治疗相关的因素包括白人种族(调整后的优势比[aOR],1.34;P <.001)、较低的合并症指数(aOR,1.11;P <.001)、拥有私人保险(aOR,1.11;P <.001)以及较高的收入中位数(aOR,1.24;P <.001)。与单中心治疗相比,碎片化治疗与更差的总生存期相关(中位生存期,60个月对65个月;P <.001)。当治疗出现碎片化时,与在非CoC中心接受碎片化治疗的患者相比,在CoC认证中心接受辅助化疗的患者5年总生存率更高(中位生存期,71个月对55个月;P <.001)。
大多数肺癌患者的治疗被分散到未经CoC认证的中心,这与更差的治疗结果相关。可能需要进行区域化、获得CoC认证或改善患者就医途径,以便特定患者在维持治疗效果的同时能接受更密切的治疗。